CA2151564A1 - Monomeric insulin analog formulations - Google Patents

Monomeric insulin analog formulations

Info

Publication number
CA2151564A1
CA2151564A1 CA002151564A CA2151564A CA2151564A1 CA 2151564 A1 CA2151564 A1 CA 2151564A1 CA 002151564 A CA002151564 A CA 002151564A CA 2151564 A CA2151564 A CA 2151564A CA 2151564 A1 CA2151564 A1 CA 2151564A1
Authority
CA
Canada
Prior art keywords
insulin analog
monomeric insulin
formulations
analog formulations
protamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002151564A
Other languages
French (fr)
Other versions
CA2151564C (en
Inventor
Michael Rosario De Felippis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Michael Rosario De Felippis
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22989963&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2151564(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Michael Rosario De Felippis, Eli Lilly And Company filed Critical Michael Rosario De Felippis
Publication of CA2151564A1 publication Critical patent/CA2151564A1/en
Application granted granted Critical
Publication of CA2151564C publication Critical patent/CA2151564C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Abstract

The present invention discloses various parenteral pharmaceutical formulations, which comprise: a monomeric insulin analog, zinc, protamine, and phenolic derivative.
The analog formulations provide a prolonged duration of action. A process for preparing insulin analog-protamine formulations is also described.
CA002151564A 1994-06-16 1995-06-12 Monomeric insulin analog formulations Expired - Lifetime CA2151564C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/260,633 1994-06-16
US08/260,633 US5461031A (en) 1994-06-16 1994-06-16 Monomeric insulin analog formulations

Publications (2)

Publication Number Publication Date
CA2151564A1 true CA2151564A1 (en) 1995-12-17
CA2151564C CA2151564C (en) 2003-02-11

Family

ID=22989963

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002151564A Expired - Lifetime CA2151564C (en) 1994-06-16 1995-06-12 Monomeric insulin analog formulations

Country Status (37)

Country Link
US (3) US5461031A (en)
JP (1) JP3812962B2 (en)
KR (1) KR100386038B1 (en)
CN (1) CN1145641C (en)
AT (1) AT408611B (en)
BE (1) BE1009409A5 (en)
BR (1) BR9502797A (en)
CA (1) CA2151564C (en)
CH (2) CH693019A5 (en)
CO (1) CO4410204A1 (en)
CZ (1) CZ294556B6 (en)
DE (1) DE19521753B4 (en)
DK (1) DK176213B1 (en)
ES (1) ES2091728B1 (en)
FI (1) FI118208B (en)
FR (1) FR2721215B1 (en)
GB (1) GB2290294B (en)
GR (1) GR1002494B (en)
HU (1) HU218943B (en)
IE (1) IE68852B1 (en)
IL (1) IL114153A (en)
IT (1) IT1276722B1 (en)
LU (1) LU88627A1 (en)
MY (1) MY116831A (en)
NL (2) NL1000565C2 (en)
NO (1) NO320808B1 (en)
NZ (1) NZ272360A (en)
PE (1) PE34496A1 (en)
PL (1) PL183284B1 (en)
PT (1) PT101723B (en)
RO (1) RO115124B1 (en)
SE (1) SE509295C2 (en)
SI (1) SI9500199A (en)
TW (1) TW347334B (en)
UA (1) UA34468C2 (en)
YU (1) YU39795A (en)
ZA (1) ZA954941B (en)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6024090A (en) * 1993-01-29 2000-02-15 Aradigm Corporation Method of treating a diabetic patient by aerosolized administration of insulin lispro
EP1607086A1 (en) * 1993-01-29 2005-12-21 Aradigm Corporation Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
US5888477A (en) * 1993-01-29 1999-03-30 Aradigm Corporation Use of monomeric insulin as a means for improving the bioavailability of inhaled insulin
US6131567A (en) * 1993-01-29 2000-10-17 Aradigm Corporation Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
DK72793D0 (en) * 1993-06-21 1993-06-21 Novo Nordisk As NEW PRODUCT
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5547929A (en) * 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
AR002976A1 (en) * 1995-03-31 1998-05-27 Lilly Co Eli PARENTERAL PHARMACEUTICAL FORMULATIONS OF LONG-TERM EFFECT OF INSULIN; CRYSTALS OF SUCH ANALOGUES APPLICABLE IN SUCH FORMULATIONS AND PROCEDURE OF THE FORMULATIONS MENTIONED
AU6299596A (en) * 1995-06-30 1997-02-05 Novo Nordisk A/S Prevention of a disease having the characteristics of diabetes
WO1997048414A1 (en) * 1996-06-20 1997-12-24 Novo Nordisk A/S INSULIN PREPARATIONS CONTAINING NaCl
US5898067A (en) * 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
DE69829953T2 (en) * 1997-02-07 2006-03-02 Novo Nordisk A/S CRYSTALLIZATION OF PROTEINS
SI0884053T1 (en) * 1997-06-13 2003-02-28 Eli Lilly And Company Stable insulin formulations
PE79099A1 (en) * 1997-06-13 1999-08-24 Lilly Co Eli STABLE INSULIN FORMULATIONS
US6268335B1 (en) * 1997-10-24 2001-07-31 Eli Lilly And Company Insoluble insulin compositions
CO4970787A1 (en) * 1997-12-23 2000-11-07 Lilly Co Eli INSOLUBLE COMPOSITIONS OF INSULIN AND INSULIN DERIVATIVES THAT CONTROL BLOOD GLUCOSE
US20010053761A1 (en) * 1998-01-08 2001-12-20 Dimarchi Richard Dennis Method for administering aspb28-human insulin
US20040214747A1 (en) * 1999-01-06 2004-10-28 Dimarchi Richard Dennis Method for administering monomeric insulin
US6624141B1 (en) 1999-03-17 2003-09-23 The Regents Of The University Of Michigan Protamine fragment compositions and methods of use
US7169889B1 (en) 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
US20030054015A1 (en) * 2000-12-25 2003-03-20 Shinichiro Haze Sympathetic-activating perfume composition
DK1358209T3 (en) * 2001-02-09 2007-05-07 Genentech Inc Crystallization of IGF-1
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6867183B2 (en) 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828305B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6835802B2 (en) * 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
WO2003020201A2 (en) * 2001-08-28 2003-03-13 Eli Lilly And Company Pre-mixes of glp-1 and basal insulin
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US7312192B2 (en) 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7166571B2 (en) 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7196059B2 (en) 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US6913903B2 (en) 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US20030068361A1 (en) * 2001-10-09 2003-04-10 Rimona Margalit Liposome-encapsulated insulin formulations
EP1448222A4 (en) * 2001-10-19 2006-05-17 Lilly Co Eli Biphasic mixtures of glp-1 and insulin
AU2002346491A1 (en) * 2001-12-19 2003-07-09 Eli Lilly And Company Crystalline compositions for controlling blood glucose
US7601688B2 (en) * 2002-06-13 2009-10-13 Biocon Limited Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
US20060258561A1 (en) * 2003-03-13 2006-11-16 Novo Nordisk A/S Novel NPH insulin preparations
CA2528741A1 (en) 2003-06-17 2004-12-23 Sembiosys Genetics Inc. Methods for the production of insulin in plants
US20050054818A1 (en) * 2003-07-02 2005-03-10 Brader Mark Laurence Crystalline compositions for controlling blood glucose
EP2085406A1 (en) * 2003-07-25 2009-08-05 ConjuChem Biotechnologies Inc. Long lasting insulin derivatives and methods thereof
EP1711220A1 (en) * 2004-01-16 2006-10-18 Biodel, Inc. Sublingual drug delivery device
US20080096800A1 (en) * 2004-03-12 2008-04-24 Biodel, Inc. Rapid mucosal gel or film insulin compositions
US7279457B2 (en) * 2004-03-12 2007-10-09 Biodel, Inc. Rapid acting drug delivery compositions
US20080085298A1 (en) * 2004-03-12 2008-04-10 Biodel, Inc. Rapid Mucosal Gel or Film Insulin Compositions
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
EP1773878B1 (en) 2004-07-19 2015-03-04 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
KR20070085227A (en) * 2004-08-09 2007-08-27 앨리오스 바이오파마 인크. Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
HUE048806T2 (en) * 2004-10-05 2020-08-28 Novo Nordisk As Pharmaceutical preparation containing insulin in crystalline as well as in solubilized form
CN101060856B (en) 2004-11-22 2011-01-19 诺和诺德公司 Soluble, stable insulin-containing formulations with a protamine salt
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
US8084420B2 (en) * 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
US7713929B2 (en) * 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
CN100371346C (en) * 2005-12-14 2008-02-27 浙江大学 Artificial synthesized insulin-simulated peptide and its application
DE602007009496D1 (en) * 2006-02-27 2010-11-11 Novo Nordisk As INSULIN DERIVATIVES
US8927015B2 (en) 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin
MX2008013165A (en) * 2006-04-12 2009-01-29 Biodel Inc Rapid acting and long acting insulin combination formulations.
CN101062948B (en) * 2006-04-29 2010-05-12 上海生物泰生命科学研究有限公司 Monomer quick-effective insulin and preparation method and usage thereof
WO2008124522A2 (en) * 2007-04-04 2008-10-16 Biodel, Inc. Amylin formulations
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
WO2009050738A2 (en) 2007-10-16 2009-04-23 Biocon Limited An orally administerable solid pharmaceutical composition and a process thereof
US20090175840A1 (en) * 2008-01-04 2009-07-09 Biodel, Inc. Insulin formulations for insulin release as a function of tissue glucose levels
ES2477552T3 (en) 2008-09-08 2014-07-17 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase activity and methods of use thereof
WO2010062308A1 (en) 2008-10-28 2010-06-03 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase and methods of use thereof
JP2012516340A (en) 2009-01-28 2012-07-19 スマートセルズ・インコーポレイテツド Synthetic conjugates and uses thereof
EA027757B1 (en) * 2009-01-28 2017-08-31 Смартселлз, Инк. Conjugate for controlled insulin delivery
US20110293562A1 (en) 2009-02-12 2011-12-01 Proyecto De Biomedicina Cima, S.L. Use of cardiotrophin-1 for the treatment of metabolic diseases
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
WO2010107519A1 (en) 2009-03-20 2010-09-23 Smartcells, Inc. Terminally-functionalized conjugates and uses thereof
HUP0900482A2 (en) * 2009-08-03 2011-03-28 Cera Med Kft Pharmaceutical formulation for oral administration
JP2013535467A (en) 2010-07-28 2013-09-12 スマートセルズ・インコーポレイテツド Recombinantly expressed insulin polypeptide and uses thereof
CA2812102A1 (en) * 2010-11-24 2012-06-07 Durect Corporation Biodegradable drug delivery composition
UY33872A (en) 2011-01-20 2012-08-31 Zealand Pharma As USE OF ACILATED GLUCAGON ANALOGS
WO2012149106A1 (en) 2011-04-29 2012-11-01 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
JP6735561B2 (en) 2012-12-03 2020-08-05 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． O-glycosylated carboxy-terminal portion (CTP) peptide-based insulin and insulin analogs
KR20150135332A (en) 2013-03-14 2015-12-02 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
BR112016007176A2 (en) 2013-10-04 2018-01-23 Merck Sharp & Dohme conjugate, composition, uses of a conjugate and composition, and method for treating an individual having diabetes
EP3079668A1 (en) 2013-12-09 2016-10-19 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
BR112016013832A2 (en) * 2014-01-09 2017-08-08 Sanofi Sa USE OF INSULIN ANALOG AND/OR DERIVATIVE, PHARMACEUTICAL FORMULATION AND PROCESS FOR THE PREPARATION OF THE SAME, KIT AND MEDICAL DEVICE
WO2015106269A2 (en) * 2014-01-13 2015-07-16 Thermalin Diabetes, Llc Rapid action insulin formulations and pharmaceutical delivery systems
AR099569A1 (en) 2014-02-28 2016-08-03 Novo Nordisk As INSULIN DERIVATIVES AND THE MEDICAL USES OF THESE
ES2630106T3 (en) 2014-10-07 2017-08-18 Cyprumed Gmbh Pharmaceutical formulations for oral administration of peptide or protein drugs
WO2017163159A1 (en) 2016-03-21 2017-09-28 Wockhardt Limited Biphasic pharmaceutical composition of insulin human
EP4360651A2 (en) 2017-08-24 2024-05-01 Novo Nordisk A/S Glp-1 compositions and uses thereof
US11110063B2 (en) 2017-08-25 2021-09-07 MAIA Pharmaceuticals, Inc. Storage stable sincalide formulations
US11820805B2 (en) 2017-12-18 2023-11-21 Merck Sharp & Dohme Llc Conjugate based systems for controlled insulin delivery
US11413352B2 (en) 2017-12-18 2022-08-16 Merck, Sharp & Dohme LLC Conjugate based systems for controlled insulin delivery
CN110063932A (en) * 2019-04-12 2019-07-30 浙江大学 A kind of slow releasing composition preparation of polypeptide protein class drug and preparation method thereof
EP4106724A1 (en) 2020-02-18 2022-12-28 Novo Nordisk A/S Glp-1 compositions and uses thereof
GB2610490A (en) 2020-03-31 2023-03-08 Protomer Tech Inc Conjugates for selective responsiveness to vicinal diols
EP4247429A1 (en) 2020-11-19 2023-09-27 Protomer Technologies Inc. Aromatic boron-containing compounds and insulin analogs
WO2023225534A1 (en) 2022-05-18 2023-11-23 Protomer Technologies Inc. Aromatic boron-containing compounds and related insulin analogs

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2538018A (en) * 1944-04-04 1951-01-16 Nordisk Insulinlab Crystalline product of insulin and alkaline protein and process of making it
US2801953A (en) * 1952-02-28 1957-08-06 Hoechst Ag Process of preparing crystallized insulin preparations
US2849370A (en) * 1953-06-04 1958-08-26 Novo Terapeutisk Labortorium A Injectable insulin preparations with protracted effect and process of producing same
US3060093A (en) * 1957-07-18 1962-10-23 Nordisk Insulinlab Slowly acting insulin preparation in crystalline form and method of preparation
US3868358A (en) * 1971-04-30 1975-02-25 Lilly Co Eli Protamine-insulin product
DE3326473A1 (en) * 1983-07-22 1985-01-31 Hoechst Ag, 6230 Frankfurt PHARMACEUTICAL AGENT FOR TREATING THE DIABETES MELLITUS
DE3327709A1 (en) * 1983-07-29 1985-02-07 Hoechst Ag, 6230 Frankfurt INSULIN DERIVATIVE CRYSTAL SUSPENSIONS, METHOD FOR THE PRODUCTION AND USE THEREOF
DK119785D0 (en) * 1985-03-15 1985-03-15 Nordisk Gentofte INSULIN PREPARATION
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
ES2053723T3 (en) * 1987-02-25 1994-08-01 Novo Nordisk As NEW INSULIN DERIVATIVES.
DE3717370A1 (en) * 1987-05-22 1988-12-01 Hoechst Ag MIXED CRYSTALS FROM INSULIN AND INSULINE DERIVATIVES, METHOD FOR THE PRODUCTION OF THESE MIXED CRYSTALS, PHARMACEUTICAL AGENTS CONTAINING THESE MIXED CRYSTALS AND THEIR USE FOR TREATING DIABETES MELLITUS
KR900701842A (en) * 1988-07-20 1990-12-04 헨리 브뢰늄 Human insulin homologues and formulations comprising them
JPH04502465A (en) * 1988-12-23 1992-05-07 ノボ　ノルディスク　アクティーゼルスカブ human insulin analogue
US5514646A (en) * 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
NZ232375A (en) * 1989-02-09 1992-04-28 Lilly Co Eli Insulin analogues modified at b29
ES2130428T3 (en) * 1993-06-21 1999-07-01 Novo Nordisk As INSULIN CRYSTALS ASP-B28.
DK72793D0 (en) * 1993-06-21 1993-06-21 Novo Nordisk As NEW PRODUCT
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations

Also Published As

Publication number Publication date
BE1009409A5 (en) 1997-03-04
GR1002494B (en) 1996-12-12
HU218943B (en) 2001-01-29
NL1004643A1 (en) 1996-12-17
JP3812962B2 (en) 2006-08-23
ATA101795A (en) 2001-06-15
SE9502168D0 (en) 1995-06-14
KR100386038B1 (en) 2003-08-27
FI952932A0 (en) 1995-06-14
NO320808B1 (en) 2006-01-30
US5747642A (en) 1998-05-05
SE9502168L (en) 1995-12-17
IE950435A1 (en) 1995-12-27
MY116831A (en) 2004-04-30
ES2091728B1 (en) 1998-02-01
CH693019A5 (en) 2003-01-31
NO952356D0 (en) 1995-06-14
IL114153A (en) 2000-09-28
PL183284B1 (en) 2002-06-28
TW347334B (en) 1998-12-11
CA2151564C (en) 2003-02-11
DK67695A (en) 1995-12-17
YU39795A (en) 1998-05-15
US5461031A (en) 1995-10-24
IL114153A0 (en) 1995-10-31
NL1004643C2 (en) 1997-02-12
CO4410204A1 (en) 1997-01-09
DK176213B1 (en) 2007-02-12
PT101723B (en) 1997-02-28
FR2721215B1 (en) 1997-08-14
NL1000565C2 (en) 1996-12-03
PT101723A (en) 1995-12-29
NO952356L (en) 1995-12-18
IT1276722B1 (en) 1997-11-03
US5650486A (en) 1997-07-22
JPH083064A (en) 1996-01-09
GB9512105D0 (en) 1995-08-09
AT408611B (en) 2002-01-25
IE68852B1 (en) 1996-07-24
PE34496A1 (en) 1996-10-01
NZ272360A (en) 1997-02-24
BR9502797A (en) 1996-03-12
CN1145641C (en) 2004-04-14
NL1000565A1 (en) 1995-12-18
CH689934A5 (en) 2000-02-15
ES2091728A1 (en) 1996-11-01
CZ154395A3 (en) 1996-02-14
PL309100A1 (en) 1995-12-27
GB2290294A (en) 1995-12-20
CN1116629A (en) 1996-02-14
CZ294556B6 (en) 2005-02-16
DE19521753B4 (en) 2009-07-23
FI952932A (en) 1995-12-17
GB2290294B (en) 1999-03-17
SE509295C2 (en) 1999-01-11
KR960000923A (en) 1996-01-25
HUT71908A (en) 1996-02-28
RO115124B1 (en) 1999-11-30
FI118208B (en) 2007-08-31
SI9500199A (en) 1996-02-29
ZA954941B (en) 1996-12-17
DE19521753A1 (en) 1995-12-21
ITMI951277A1 (en) 1996-12-14
HU9501717D0 (en) 1995-08-28
ITMI951277A0 (en) 1995-06-14
FR2721215A1 (en) 1995-12-22
LU88627A1 (en) 1996-02-01
UA34468C2 (en) 2001-03-15

Similar Documents

Publication Publication Date Title
CA2151564A1 (en) Monomeric insulin analog formulations
EP1090640A3 (en) Insulin analog formulations
ZA962502B (en) Monomeric insulin analog formulations.
AU691361B2 (en) Novel 2,3-diketopiperazine derivative or salt thereof
AU6627990A (en) Biosignal electrode
AU4642393A (en) Medication sprayer
AU3299293A (en) New pyrethrinoid esters derived from thiazolic alcohols, their preparation process and their use as pesticides
AU5229690A (en) Polyamide 4.6 composition
AU3263493A (en) Tonometer
AU8388691A (en) Substituted 1,2,4-triazinediones, processes for their preparation, intermediates therefor and their use
AU673401B2 (en) 6,7-dialkoxy-3,4-dihydroisoquinolin-8-ol, process for preparation thereof and process for preparation of 6,7-dialkoxy-1,2,3,4-tetrahydroisoquinolin-8-ol using the compound
AU3709689A (en) Substituted 4-sulphonylamino-2-azinyl-1,2,4-traizol-3-ones, processes and intermediates for their preparation and their use as herbicides
AU5388090A (en) N-sulfenyl- and n-sulfinyl-n,n'-diacylhydrazides
AU6511294A (en) Tonometer
AU5808294A (en) A process for the preparation of 2,3,5,6-tetrachloropyridine
AU9198698A (en) Process for the preparation of substituted 5,6-dihydro-2h-pyran-2-ones
AU8482791A (en) Cyclohexane oxidation
AU4762993A (en) Keratometer
AU5066693A (en) Process for the preparation of 5,6-diacetoxyindole
AU1681895A (en) Process for preparing 4,4-dialkyl-6-halo-chromans or thiochromans useful as pharmaceutical intermediates
AU595786B3 (en) Spray head assembly
AU666799B2 (en) N-aryloxyacyl-n-phenyltetrahydrophthalamic acid derivative, process for producing the same, and herbicide containing the same as active ingredient
AU677262B2 (en) N-acyl-n-phenylmaleamic acid derivative, process for producing the same, and herbicide containing the same as active ingredient
AU684260B2 (en) 1,4-benzoxazine-2-acetic acid compound, process for producing the same, and use thereof
AU2168295A (en) Monomeric insulin analog formulations

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20150612